Tjaša Gortnar Cepeda

Tjaša Gortnar Cepeda

Auto-generated profile, based on publicly available information

Tjaša Gortnar Cepeda

Medicinska fakulteta Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenija

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
CKCvetka Grašič Kuhar
Cvetka Grašič Kuhar
TCTjaša Gortnar Cepeda
Tjaša Gortnar Cepeda
TKTimotej Kovač
Timotej Kovač
MKMatjaz Kukar
Matjaz Kukar
NGNina Ružić Gorenjec
Nina Ružić Gorenjec
Background: Providing patients with cancer who are undergoing systemic therapy with useful information about symptom management is essential to prevent unnecessary deterioration of quality of life. Objective: The aim was to evaluate whether use of an app for symptom management was associated with any change in patient quality of life or use of health resources. Methods: Outpatients with early stage breast cancer receiving systemic therapy were recruited at the Institute of Oncology in Ljubljana, Slovenia. Patients who received systemic therapy between December 2017 and March 2018 (control group) and between April 2018 and September 2018 (intervention group) were eligible. All patients received standard care, but only those in the intervention group were asked to use mPRO Mamma, an Android-based smartphone app, in addition. The app supported daily tracking of 50 symptoms, allowed users to grade their symptom severity (as mild, moderate, or severe), and also provided in-depth descriptions and recommendations based on reported symptom level. Patient-reported outcomes in both groups were assessed through the European Organisation for Research and Treatment of Cancer (EORTC) core (C-30) and breast cancer (BR-23) questionnaires, as well as a questionnaire about health resources use. The primary outcomes were the difference in the global quality of life between groups and the difference in summary score of the EORTC C-30 questionnaire between groups after 3 time periods (the first week of treatment, the first treatment cycle, and the entire treatment). The secondary outcome was the use of health resources (doctor visits and hospitalizations) in each time period. Other scales were used for exploratory analysis. Results: The mean difference between the intervention group (n=46) and the control group (n=45) in global quality of life (adjusted for baseline and type of surgery) after the first week was 10.1 (95% CI 1.8 to 18.5, P=.02). The intervention group summary scores were significantly higher than those of the control group after the first week (adjusted mean difference: 8.9, 95% CI 3.1 to 14.7, P=.003) and at the end of treatment (adjusted mean difference: 10.6, 95% CI 3.9 to 17.3, P=.002). Use of health resources was not statistically significant between the groups in either the first week (P=.12) or the first treatment cycle (P=.13). Exploratory analysis findings demonstrated clinically important improvements (indicated by EORTC C-30 or BR-23 scale scores)—social, physical, role, and cognitive function were improved while pain, appetite loss, and systemic therapy side effects were reduced. Conclusions: Use of the app enabled patients undergoing systemic therapy for early stage breast cancer to better cope with symptoms which was demonstrated by a better global quality of life and summary score after the first week and by a better summary score at the end of treatment in the intervention group compared to those of the control group, but no change in the use of health resources was demonstrated.

11 December 2019 in JMIR Preprints
Verified
Preprint
Open access
CKCvetka Grašič Kuhar
Cvetka Grašič Kuhar
TCTjaša Gortnar Cepeda
Tjaša Gortnar Cepeda
TKTimotej Kovač
Timotej Kovač
MKMatjaz Kukar
Matjaz Kukar
NGNina Ružić Gorenjec
Nina Ružić Gorenjec
BACKGROUND Providing patients with cancer who are undergoing systemic therapy with useful information about symptom management is essential to prevent unnecessary deterioration of quality of life. OBJECTIVE The aim was to evaluate whether use of an app for symptom management was associated with any change in patient quality of life or use of health resources. METHODS Outpatients with early stage breast cancer receiving systemic therapy were recruited at the Institute of Oncology in Ljubljana, Slovenia. Patients who received systemic therapy between December 2017 and March 2018 (control group) and between April 2018 and September 2018 (intervention group) were eligible. All patients received standard care, but only those in the intervention group were asked to use mPRO Mamma, an Android-based smartphone app, in addition. The app supported daily tracking of 50 symptoms, allowed users to grade their symptom severity (as mild, moderate, or severe), and also provided in-depth descriptions and recommendations based on reported symptom level. Patient-reported outcomes in both groups were assessed through the European Organisation for Research and Treatment of Cancer (EORTC) core (C-30) and breast cancer (BR-23) questionnaires, as well as a questionnaire about health resources use. The primary outcomes were the difference in the global quality of life between groups and the difference in summary score of the EORTC C-30 questionnaire between groups after 3 time periods (the first week of treatment, the first treatment cycle, and the entire treatment). The secondary outcome was the use of health resources (doctor visits and hospitalizations) in each time period. Other scales were used for exploratory analysis. RESULTS The mean difference between the intervention group (n=46) and the control group (n=45) in global quality of life (adjusted for baseline and type of surgery) after the first week was 10.1 (95% CI 1.8 to 18.5, P=.02). The intervention group summary scores were significantly higher than those of the control group after the first week (adjusted mean difference: 8.9, 95% CI 3.1 to 14.7, P=.003) and at the end of treatment (adjusted mean difference: 10.6, 95% CI 3.9 to 17.3, P=.002). Use of health resources was not statistically significant between the groups in either the first week (P=.12) or the first treatment cycle (P=.13). Exploratory analysis findings demonstrated clinically important improvements (indicated by EORTC C-30 or BR-23 scale scores)—social, physical, role, and cognitive function were improved while pain, appetite loss, and systemic therapy side effects were reduced. CONCLUSIONS Use of the app enabled patients undergoing systemic therapy for early stage breast cancer to better cope with symptoms which was demonstrated by a better global quality of life and summary score after the first week and by a better summary score at the end of treatment in the intervention group compared to those of the control group, but no change in the use of health resources was demonstrated.

9 June 2022 in Anali PAZU
Verified
Journal Article
Closed access
PDF file
CKCvetka Grašič Kuhar
Cvetka Grašič Kuhar
EDEva Drmota
Eva Drmota
TGTjaša Gortnar
Tjaša Gortnar
TKTimotej Kovač
Timotej Kovač
MKMatjaz Kukar
Matjaz Kukar
Cancer patients on chemotherapy treatment may have several symptoms. In the study Mobile application for patients with breast cancer treated with chemotherapy and targeted therapy patients reported symptoms by means of mobile application. Patient could report 50 symptoms. Patient having a specific symptom, defines a severity (mild, moderate or severe) and its duration. We performed analysis on 16 patients for the first cycle of chemotherapy. The most prevalent symptoms were fatigue (75%), dry mouth, headache, redness of the face (56%), myalgia, hoarsenes, heartburn, meteorism (31%), obstipation, diarrhoea (25%) and alopecia (44%). The majority of symptoms were mild or moderate and short lasting (less than 4 days). Reporting symptoms is of great help for the treating oncologist for better symptom treatment.